Prediabetes

The risk for subclinical atherosclerosis among people at low risk for cardiovascular death increases with increasing glycated hemoglobin levels and is raised even at levels below the prediabetes threshold, research shows.

The risk for adverse cardiorenal events begins to increase well below the glycemic level associated with type 2 diabetes, with the largest proportion of events occurring in people with prediabetic levels, shows a UK Biobank analysis.

A random blood glucose test in people without diabetes may provide a good indication of who has an increased risk for developing cardiovascular disease over the subsequent decade, a study suggests.

Delaying progression from impaired glucose tolerance to type 2 diabetes reduces the risk for micro- and macrovascular complications, shows 24 years of follow-up of the Da Qing trial.

Adults who develop prediabetes when older than 70 years are more likely to regress to normoglycemia or die of other causes than to progress to type 2 diabetes, research shows.

A randomized trial indicates that testosterone treatment among men with prediabetes or newly diagnosed type 2 diabetes significantly reduces the risk for them having type 2 diabetes 2 years later.

The SGLT2 inhibitor empagliflozin may reverse adverse left ventricular remodeling in people who have heart failure with reduced ejection fraction and type 2 diabetes or prediabetes, shows a randomized trial.

Lifestyle intervention significantly reduces the risk for type 2 diabetes in people who have prediabetes based on fasting plasma glucose or glycated hemoglobin measurements, show findings from a randomized trial.

The excess risk for myocardial infarction associated with having diabetes may be greater in women than men, despite men having a higher frequency of events overall, shows research from the UK Biobank.

Prediabetes is associated with an elevated risk for all-cause mortality and cardiovascular events, both in the general population and in patients with atherosclerotic cardiovascular disease, shows an updated meta-analysis published in The BMJ.

Focusing efforts on convincing people to return after the first session of the US National Diabetes Prevention Program lifestyle change program, and after the transition to less frequent sessions, may help to optimize program retention, say researchers.

The increased risk for prediabetes among ethnic minorities compared with White people is less pronounced in neighborhoods with high walkability, shows a Canadian study.

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.

A study shows marked variations in cardiovascular risk burden according to age, sex, and ethnicity at the point of type 2 diabetes diagnosis, with implications for both diabetes prevention and cardiovascular risk management.

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

Liraglutide 3.0 mg boosts weight loss in obese adolescents receiving lifestyle therapy, show the findings of a phase 3 trial.

Severely obese people show evidence of impaired cognition even when they have no signs of prediabetes or diabetes, but retinopathy and nephropathy only occur in those with hyperglycemia, US research shows.

Symptoms of anxiety are associated with an increased risk for progression from prediabetes to type 2 diabetes, indicate findings from a population-based study.

Insulin resistance may be a more important determinant of type 2 diabetes risk in Chinese people than impaired beta-cell function, show findings from a large population-based study.

The prevalence of diabetes is elevated in non-White US ethnic groups, but varies markedly within those groups, show data from the NHANES survey.